AI home‑monitoring saves only in some AMD cases

Age-related macular degeneration damages the center of the retina, and the “wet” form can leak fluid fast enough to blur vision between office visits. A new American Journal of Managed Care explainer says home eye scans paired with artificial intelligence can catch those changes sooner, but the math does not save money for every patient. (ajmc.com) Doctors now track wet age-related macular degeneration with optical coherence tomography, a light-based scan that works like an ultrasound for the retina, plus repeated anti-vascular endothelial growth factor injections. The contributor piece says home optical coherence tomography adds daily monitoring between clinic appointments instead of relying on scans taken every one to two months. (clinicaltrials.gov) The article centers on neovascular age-related macular degeneration, which it says affects an estimated 1.49 million Americans. It argues that remote monitoring looks best economically in patients who need frequent injections, because fewer unnecessary treatments can offset device fees and image-reading costs. (ajmc.com) That conditional result cuts against a simple “artificial intelligence saves money” pitch now circulating in ophthalmology. The same American Academy of Ophthalmology meeting presentation cited by the piece estimated a 28% drop in drug costs from reduced treatment, but it also described new monthly billing for remote optical coherence tomography under Current Procedural Terminology codes 0604T, 0605T, and 0606T. (aao.org) The evidence behind the monitoring claim is still early and mostly based on how specialists say they would act with more data, not on completed randomized outcome trials. In a Journal of Vitreoretinal Diseases study published online on December 7, 2024, 15 retina specialists reviewed 150 home-scan segments from 29 eyes and said treatment could have been withheld in 42.7% of cases and given at least 7 days earlier in 60.5% of cases that they judged needed treatment. (pubmed.ncbi.nlm.nih.gov) The hardware itself is also new. The Food and Drug Administration granted De Novo authorization on May 16, 2024, for Notal Vision’s home optical coherence tomography system for eyes diagnosed with neovascular age-related macular degeneration, making it the first cleared home retinal imaging service of its kind for that use. (accessdata.fda.gov) Supporters say the appeal is precision. The American Academy of Ophthalmology said physicians reviewing home-scan histories for 37 eyes agreed with the original office-only treatment timing in just 23% of cases, recommended delaying treatment in nearly 42%, and recommended giving treatment at least a week earlier in 35%. (aao.org) Skeptics point to what has not been proved yet: whether daily home scanning improves vision over years, reduces injections in routine practice, and works outside selected patients who can operate the device consistently. A 104-week randomized trial sponsored by the Jaeb Center for Health Research was still recruiting as of its January 29, 2026 update on ClinicalTrials.gov. (clinicaltrials.gov) For now, the economics look less like a blanket win than a triage tool for a high-burden disease. The American Journal of Managed Care piece lands on a narrower claim: home optical coherence tomography with artificial intelligence may pay off when treatment burden is high enough to outweigh the added monitoring bill. (ajmc.com)